Lenvatinib + Pembrolizumab in Treatment-Naive or Previously Treated mRCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Lenvatinib Plus Pembrolizumab in Patients With Either Treatment-Naive or Previously Treated Metastatic Renal Cell Carcinoma (Study 111/KEYNOTE-146): A Phase 1b/2 Study
Lancet Oncol 2021 Jul 01;22(7)946-958, CH Lee, AY Shah, D Rasco, A Rao, MH Taylor, C Di Simone, JJ Hsieh, A Pinto, DR Shaffer, R Girones Sarrio, AL Cohn, NJ Vogelzang, MA Bilen, S Gunnestad Ribe, M Goksel, ØK Tennøe, D Richards, RF Sweis, J Courtright, D Heinrich, S Jain, J Wu, EV Schmidt, RF Perini, P Kubiak, CE Okpara, AD Smith, RJ MotzerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.